momentum continu resm unveil multipl product
initi new mask technolog
page full analyst note apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data jun
rate updat jun
currenc amount express
valuat growth profit
methodolog valu compani
target larg potenti market opportun
nation heart blood lung institut estim
million american suffer sleep apnoea accord
fewer million diagnos
treat sleep apnoea year expand pool
diagnos treat sleep apnoea patient compani
target disord much gain
strategi involv increas awar disord
among physician gener popul compani
also make test sleep apnoea simpler home
test devic expand compani reach
patient unwil treat sleep lab
importantli aim introduc new devic
make patient comfort compliant
treatment provid compani stream
recur revenu
oan age popul coupl acceler obes
trend drive signific growth
steadi rate innov differenti
advantag histor support premium
omount evid clinic relev sleep
condit --
hypertens diabet -- increas demand
medic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop manufactur distribut medic devic --
airflow gener mask -- treat breath disord also market
ventil product sleep apnoea remain compani primari
focu reach truli global distribut capabl
countri wholli own independ firm
increas proport manufactur capac singapor
still australia compani found
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bilevel devic
entri
support
momentum continu resm unveil multipl
product initi new mask technolog apr
deliv anoth solid quarter net incom
usd million group revenu usd million
year-ago third quarter
respect oper leverag major factor
sell gener administr expens
lesser degre research develop cost trend
sequenti basi also unveil sever
launch new
smartphon app screen sleep apnoea china
launch resmed-brand portabl oxygen
concentr mobi unit state follow
result rais fair valu estim narrow-
moat usd per share usd
updat oper expens assumpt incorpor
tax guidanc fiscal fiscal equat
aud per depositari interest base
australian dollar/u dollar exchang rate
aud per cdi previous consid share
current level line fair valu
includ
sleep apnoea
technolog key sourc narrow moat rate remain
intact continu benefit airsens
platform launch quarterli sale growth
third quarter robust despit cycl strong
prior correspond period across product categori
geographi expect new product initi
launch mobi roll-out new quiet
air diffus technolog quietair full-fac mask
reimburs franc japan south korea
maintain posit momentum medium term
maintain five-year revenu compound annual
growth rate forecast devic mask
respect versu broader market growth
conjunct
third quarter devic mask sale reach
usd million usd million increas
respect year year europ asia
market impress devic mask sale usd
million usd million respect
constant currenc term buoy stronger euro gross
margin group remain stabl around
quarter consist prior correspond period
resm balanc sheet solid flow gener
remain strong support cash flow oper year
date usd million year year net debt
around usd million end march
year year forecast end fiscal
net cash posit compar net debt/ebitda
fiscal oper leverag gain past
three quarter seen sell gener administr
expens percentag group revenu trend
stabil
lower forecast sg
assumpt also lower research
develop cost assumpt slightli
incorpor guidanc
compani declar quarterli dividend usd per
share repres pay-out ratio given
strength earn modest level gear remain
comfort abil fund sharehold
manag also provid updat australian
taxat offic audit year deliv
march assert compani owe usd
million addit incom tax usd million
accru interest contest transfer price
issu pursu administr legal action
nonetheless compani agre pay
assess record liabil third quarter
pend resolut matter stage
use effect tax guidanc provid manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
technic superior devic still aim maintain
technic edg serv well far patient
difficult time adjust sleep disrupt
advanc featur lead greater patient
comfort complianc turn lead brand loyalti
patient return sleep lab home
mask pillow -- highli profit recur revenu
stream help endear custom base
face tough competit though particularli
pioneer industri possess admir market
distribut capabl addit product
synonym sleep apnoea treatment
face difficult challeng tri educ
physician product set competitor also
shown willing compet price blanket
market free sampl past new product launch
continu impress innov
success combat price eros prevent
declin return capit
think prove abil develop new
sleep apnoea treatment expect
futur consid develop capabl
larg potenti patient pool remain
undiagnos untreat sleep apnoea market
look posit continu grow fast
clip fill gap exist therapeut option
valuat growth profit apr
fair valu estim stand aud
per australian chess depositari interest cdi
calcul use australian dollar/u dollar exchang
rate adjust ratio cdi/primari
stock cost equiti use valuat line
cost equiti use valu global
medic devic compani st jude
fiscal revert fiscal
remain one key leader sleep apnoea
treatment admir innov capabl
expect compani deliv solid return long run
look forward see develop next
focus develop medic devic treat
sleep apnoea respiratori problem
educ caregiv therapi option firm
product portfolio consist airflow gener nasal
mask pillow introduc airflow need
prop open patient respiratori pathway sleep
tool help patient breath easier avoid
complic associ sleep apnoea includ
exhaust hypertens gener half
sale half sale
throughout europ japan
second mover sleep apnoea devic
initi forc play catch-up differenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
grow portfolio respiratori product focus copd
neuromuscular diseas cardio-respiratori condit
underpin posit stanc compani strong
competit posit market educ
effort rais clinic profil sleep-disord
breath increas awar sleep apnoea
particular despit sign increas competit mask
low-tech end flow gener believ
integr product suit creat applic
switch cost clinician patient key aspect
latest product offer built-in wireless
connect togeth on-line data informat
manag tool clinician bode well patient
support despit serve-hf trial setback clinic
evid date link sleep-disord breath host
medic disord beyond cardiolog repres futur
commerci opportun
treatment efficaci
sleep apnoea
view moat trend stabl
philip electron formerli respiron effect
duopoli domin market sleep apnoea
devic decad absenc potenti
disruptor horizon see chang
time soon proven abil innov
market healthcar stakehold think firm
remain leader market forese futur
expect momentum new product develop
maintain given on-going research develop
spend revenu
next four year expect key demograph
trend age obes increas penetr
potenti patient pool greater awar
conveni test option drive compound
annual sale growth firm assum
competit environ five-year period
result limit scale economi firm increas
compani reach patient expect
educ home test initi
firm profit expand faster base forecast
either better oper effici stronger
dollar/australian dollar translat consid
rais fair valu estim aud per cdi
scenario assum sale increas
compound annual basi next five year effect
demand product deceler result
competit threat margin contract either
oper ineffici weaker dollar
consid lower fair valu estim aud
per cdi scenario assum sale increas
compound annual basi next five
assign narrow moat rate base
intang asset switch cost given strong track
record innov product introduct coupl
solid patent posit dug narrow econom
moat around busi develop
market capabl sleep apnoea devic new
product launch core sleep apnoea busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
target larg under-penetrated sleep-
disord breath market growth continu
strong trajectori patient incorpor
non-invasive treatment sleep
owith focu shift toward complianc rather
low-cost system thrive given
histori introduc innov product
oa signific boost at-hom sleep apnoea test
could open market patient object
costli uncomfort test sleep lab
abil sell product depend larg
willing third parti pay treatment
lower reimburs rate product
would hurt revenu margin potenti
research
develop unabl introduc new product
marketplac success sale margin
ocompetit sampl hurt growth recent
year practic return attract
sleep apnoea devic market could diminish
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
nearli usd million cash cash equival
june compar usd million
total debt remain excel financi health
given abil gener signific free cash flow
expect posit strengthen futur year
like medical-devic firm must innov
face signific price pressur compani may
abl stay head innov class futur
year would creat open competitor
compani also face foreign exchang risk substanti
develop manufactur oper remain
australia firm found
sale dispers throughout rest
world account half sale
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
bae system employe save invest
govern pension fund norway global
share
fund
share
fund
strong free cash flow gener intern
fund growth mani year issu fresh equiti
employ rel littl debt return invest
capit consist well cost capit
upward trend recent year major
growth follow three major contributor effect
invest research develop maintain
technolog invest clinic trial demonstr
medic benefit treat condit
distribut expertis reach
commend manag avers debt net cash
level somewhat excess opinion given limit
past question manag
zero-dividend polici prefer intermitt
repurchas stock manag credit
done price gener prove value-accret
pleas firm initi dividend
acquisit strategi buy rel small
firm complementari technolog intellectu
properti seen manag risk materi
amount capit acquisit found
value-destruct
ceo mick farrel posit sinc
son founder peter farrel compani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
momentum continu resm unveil multipl
product initi new mask technolog apr
deliv anoth solid quarter net incom
usd million group revenu usd million
year-ago third quarter
respect oper leverag major factor
sell gener administr expens
lesser degre research develop cost trend
sequenti basi also unveil sever
launch new
smartphon app screen sleep apnoea china
launch resmed-brand portabl oxygen
concentr mobi unit state follow
result rais fair valu estim narrow-
moat usd per share usd
updat oper expens assumpt incorpor
tax guidanc fiscal fiscal equat
aud per depositari interest base
australian dollar/u dollar exchang rate
aud per cdi previous consid share
current level line fair valu
includ
sleep apnoea
technolog key sourc narrow moat rate remain
intact continu benefit airsens
platform launch quarterli sale growth
third quarter robust despit cycl strong
prior correspond period across product categori
geographi expect new product initi
launch mobi roll-out new quiet
air diffus technolog quietair full-fac mask
reimburs franc japan south korea
maintain posit momentum medium term
maintain five-year revenu compound annual
growth rate forecast devic mask
respect versu broader market growth
conjunct
third quarter devic mask sale reach
usd million usd million increas
respect year year europ asia
market impress devic mask sale usd
million usd million respect
constant currenc term buoy stronger euro gross
margin group remain stabl around
quarter consist prior correspond period
resm balanc sheet solid flow gener
remain strong support cash flow oper year
date usd million year year net debt
around usd million end march
year year forecast end fiscal
net cash posit compar net debt/ebitda
fiscal oper leverag gain past
three quarter seen sell gener administr
expens percentag group revenu trend
stabil
lower forecast sg
assumpt also lower research
develop cost assumpt slightli
incorpor guidanc
compani declar quarterli dividend usd per
share repres pay-out ratio given
strength earn modest level gear remain
comfort abil fund sharehold
manag also provid updat australian
taxat offic audit year deliv
march assert compani owe usd
million addit incom tax usd million
accru interest contest transfer price
issu pursu administr legal action
nonetheless compani agre pay
assess record liabil third quarter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
current level
quarterli sale growth surpris upsid across
product rang rest-of-world mask sale hit usd
million usd million respect
constant-curr term prior
correspond period pcp row devic sale
usd million usd million respect
constant-curr term pcp
softwar solut divis hous brightre
acquisit deliv sale usd million
pcp
regard effect tax rate manag guid
fiscal onward subject
 tax reform prospect australian draft tax
legisl pass third-quart line
current
manag comment chang tax
system could support tax-effect repatri non-
invest unit state manufactur
research develop
revenu could
balanc sheet perspect think resm
gear level sustain given on-going strong cash
flow oper usd million second-
quarter almost pcp
forecast debt/adjust ebitda declin time
fiscal fiscal
pend resolut matter stage
use effect tax guidanc provid manag
fiscal revert fiscal
strong sale momentum maintain oper
leverag boost bottom line rais fve
strong sale momentum first-quart fiscal
continu narrow-moat report anoth
excel quarter ahead expect across
product categori net profit tax adjust one-off
item relat chang tax reform usd
million group revenu usd million
respect result reflect
continu adopt airsens devic platform
launch complement subsequ launch
airfit airfit mask recent
airmini maintain quarterli dividend
usd per share repres pay-out ratio
key highlight quarter sell gener
administr sg expens percentag group
revenu around manag guid
fiscal run rate
compar around
two year ago
demonstr increas oper leverag scale
global sleep apnoea space
increas fair valu estim usd per
share usd incorpor sg guidanc
percentag group revenu previous
base sale momentum first half also
increas fiscal group revenu forecast
usd million nonetheless five-year group
revenu compound-annual-growth-rate assumpt unchang
equat aud per cdi base aud/usd exchang
rate regard stock fairli valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end june
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
